DS
OLMA icon

David Shaw’s Olema Pharmaceuticals OLMA Stock Holding History

David Shaw’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$695K Buy
55,519
+16,289
+42% +$218K ﹤0.01% 3991
2026
Q1 		$585K Buy
39,230
+29,276
+294% +$652K ﹤0.01% 3772
2025
Q4 		$249K Buy
+9,954
New +$177K ﹤0.01% 4239
2025
Q1 		– Sell
-12,445
Closed -$72.6K – 4603
2024
Q4 		$72.6K Sell
12,445
-13,148
-51% -$131K ﹤0.01% 4189
2024
Q3 		$306K Buy
25,593
+4,534
+22% +$58K ﹤0.01% 3965
2024
Q2 		$228K Buy
21,059
+10,959
+109% +$119K ﹤0.01% 4027
2024
Q1 		$114K Sell
10,100
-1,789
-15% -$23.1K ﹤0.01% 3997
2023
Q4 		$167K Buy
+11,889
New +$160K ﹤0.01% 3911
2022
Q3 		– Sell
-154,081
Closed -$627K – 5427
2022
Q2 		$627K Sell
154,081
-58,289
-27% -$185K ﹤0.01% 3962
2022
Q1 		$905K Buy
212,370
+124,288
+141% +$685K ﹤0.01% 3996
2021
Q4 		$824K Buy
88,082
+20,656
+31% +$428K ﹤0.01% 4089
2021
Q3 		$1.86M Buy
67,426
+26,622
+65% +$719K ﹤0.01% 3101
2021
Q2 		$1.14M Sell
40,804
-75,725
-65% -$2.15M ﹤0.01% 3428
2021
Q1 		$3.87M Buy
+116,529
New +$4.99M ﹤0.01% 2052

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

David Shaw's OLMA Position: Q2 2026 in Review

David Shaw increased its Olema Pharmaceuticals (OLMA) stake by 42% in Q2 2026, buying an estimated $218K and bringing the position to 55,519 shares worth $695K. The position accounts for ﹤0.01% of the portfolio, ranked #3991.

David Shaw first reported a position in OLMA in Q1 2021 and has held it in 14 quarters since. The position peaked at $3.87M in Q1 2021. 182 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • David Shaw held 55,519 shares of Olema Pharmaceuticals worth $695K as of Q2 2026.
  • David Shaw bought 16,289 Olema Pharmaceuticals shares in Q2 2026, an estimated $218K.
  • Olema Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3991 holding.
  • David Shaw first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • David Shaw's Olema Pharmaceuticals position peaked at $3.87M in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.